Expertise in
22
conditions

Dr. Shiao-pei S. Weathers

Neurology
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
17 Years of Experience
Expertise in
22
conditions
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 

Overview

Shiao-pei Weathers is a Neurologist practicing medicine in Houston, Texas. She has been practicing medicine for over 17 years.

Dr. Weathers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy.

She is actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 12 clinical trials.

Graduate Year

2009

Specialties

Neurology

Licenses

Psychiatry & Neurology in MI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030

Additional Areas of Focus

Dr. Weathers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Grade 4 Astrocytoma (Glioblastoma)
A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Grade 4 Astrocytoma (Glioblastoma)
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Study Phase: Phase 1
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM)
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Biological
Study Drugs: Atezolizumab, Cabozantinib
Study Phase: Phase 1/Phase 2
Feasibility of Monitoring Step Count as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Patients Undergoing Radiation Therapy
Feasibility of Monitoring Step Count as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Patients Undergoing Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Completed
Publish Date: September 24, 2025
Intervention Type: Radiation, Drug
Study Drugs: Atezolizumab, Temozolomide
Study Phase: Phase 1/Phase 2
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: VAL-083, Dianhydrogalactitol
Study Phase: Phase 2
A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma
A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Radiation, Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Autologous Cytomegalovirus-Specific Cytotoxic T Lymphocytes, Temozolomide
Study Phase: Phase 1/Phase 2
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
View 8 Less Clinical Trials

60 Total Publications

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Baylor College Of Medicine Medical Center

7200 Cambridge St., Ste 9A, 
Houston, TX 
 (0.5 miles away)
713-798-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Jankovic is a Neurologist practicing medicine in Houston, Texas. Dr. Jankovic is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Benign Essential Blepharospasm, Drug Induced Dyskinesia, Movement Disorders, Torticollis, and Deep Brain Stimulation. Dr. Jankovic is currently accepting new patients.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Houston Methodist Department Of Neurology-Texas Medical Center

6560 Fannin St Ste 802, 
Houston, TX 
 (0.3 miles away)
713-441-3780
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tetsuo Ashizawa is a Neurologist practicing medicine in Houston, Texas. Dr. Ashizawa is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Ashizawa is currently accepting new patients in some locations.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vinay Puduvalli is a Neurologist practicing medicine in Houston, Texas. Dr. Puduvalli is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

Frequently Asked Questions about Dr. Shiao-pei S. Weathers

How do I make an appointment with Dr. Shiao-pei S. Weathers?

You can book an appointment with Dr. Shiao-pei S. Weathers by calling their office at 713-792-6600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shiao-pei S. Weathers a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shiao-pei S. Weathers is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shiao-pei S. Weathers specialize in?

While Dr. Shiao-pei S. Weathers is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Shiao-pei S. Weathers participate in research or clinical trials?

Yes. Dr. Shiao-pei S. Weathers has published 60 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Shiao-pei S. Weathers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shiao-pei S. Weathers accept my insurance?

Dr. Shiao-pei S. Weathers accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weathers's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 7 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile